Headlands Technologies LLC Grows Stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Headlands Technologies LLC increased its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 1,608.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,545 shares of the company’s stock after buying an additional 2,396 shares during the period. Headlands Technologies LLC’s holdings in Harmony Biosciences were worth $77,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the business. Hedeker Wealth LLC purchased a new stake in shares of Harmony Biosciences in the 1st quarter valued at about $2,627,000. LSV Asset Management grew its stake in Harmony Biosciences by 346.5% in the 1st quarter. LSV Asset Management now owns 335,146 shares of the company’s stock worth $11,254,000 after buying an additional 260,093 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Harmony Biosciences during the 4th quarter valued at $876,000. Hennion & Walsh Asset Management Inc. raised its position in shares of Harmony Biosciences by 214.1% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 44,945 shares of the company’s stock valued at $1,356,000 after buying an additional 30,638 shares in the last quarter. Finally, Quest Partners LLC grew its position in Harmony Biosciences by 242.1% in the second quarter. Quest Partners LLC now owns 15,034 shares of the company’s stock worth $454,000 after acquiring an additional 10,639 shares in the last quarter. Institutional investors own 86.23% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on HRMY shares. UBS Group assumed coverage on Harmony Biosciences in a research note on Tuesday, September 10th. They set a “buy” rating and a $56.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $52.00 price target on shares of Harmony Biosciences in a research report on Thursday, September 12th. Finally, Citigroup assumed coverage on shares of Harmony Biosciences in a report on Friday, June 21st. They issued a “buy” rating and a $48.00 price objective for the company. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Harmony Biosciences Trading Down 0.4 %

Shares of HRMY opened at $38.76 on Tuesday. Harmony Biosciences Holdings, Inc. has a 1-year low of $18.61 and a 1-year high of $39.73. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. The firm’s 50-day moving average price is $34.81 and its 200-day moving average price is $32.05. The firm has a market capitalization of $2.20 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 0.75 and a beta of 0.73.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.24. The business had revenue of $172.80 million for the quarter, compared to analysts’ expectations of $172.53 million. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The business’s revenue was up 28.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.56 EPS. Sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.19 EPS for the current year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.